Drug intelligence / Profile preview

NTC-510A

Development stage: Unknown
Lead developer: NanoSHIFT
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

NTC-510A is an investigational oral nanoparticle formulation of buprenorphine developed by NanoSHIFT LLC (formerly Nanotherapeutics) for the management of acute dental pain. Buprenorphine is a small molecule opioid that acts as a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. The NTC-510A formulation utilizes a proprietary nanoparticle delivery system designed to enhance the oral bioavailability of buprenorphine, which is typically low due to extensive first-pass metabolism. It has been evaluated in Phase 2 clinical trials for pain relief following third molar extraction, where it was studied alongside NTC-510, a combination formulation containing both buprenorphine and naloxone.

Other names: buprenorphine nanoparticle formulation

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on NTC-510A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTC-510A.